UNSPSC 51292004: Citalopram

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DHU5B8D6V, chemically known as 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile but generally known as citalopram, which bears US NIH Compound Identifier 2771. European Medicines Agency schedules Citalopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07485MIG.

UNSPSC 51292004 Citalopram is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent activity shows state and local governments buying a broader range of medications and drug-related products than the code's single-drug focus suggests. The most recent opportunities involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals for state health systems. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work ranges from direct purchase of finished pharmaceuticals with specified quarterly delivery schedules to longer-term framework agreements that establish pricing and supply relationships with authorized wholesalers for distribution across multiple jurisdictions.

Activity appears concentrated in Florida, Texas, and Minnesota, with a multistate cooperative mechanism (MMCAP) extending coverage to Oregon and other participating states. Representative recent solicitations include Seminole County, Florida's IFB 60459723LAS for naloxone and drug deactivation systems with quarterly deliveries (due July 26, 2023); the Texas Health and Human Services Commission's RFI HHS0017013 for direct-to-manufacturer prescription capabilities (due April 3, 2026); and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with a March 26, 2026 response deadline and July 1, 2026 contract effective date. Contracts typically require FDA compliance, cGMP certification where applicable, comprehensive insurance coverage, and E-Verify employment verification. Awards span two-year terms with renewal options, and pricing models vary from unit-cost fixed-fee arrangements to WAC-minus and net-price structures with administrative fees.